Goldman Sachs’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-12,320
| Closed | -$1.6K | – | 6415 |
|
|
2025
Q3 | $1.6K | Buy |
+12,320
| New | +$1.69K | ﹤0.01% | 6287 |
|
|
2025
Q2 | – | Sell |
-16,149
| Closed | -$3.18K | – | 6052 |
|
|
2025
Q1 | $3.18K | Sell |
16,149
-11
| -0.1% | -$6 | ﹤0.01% | 6000 |
|
|
2024
Q4 | $8.71K | Sell |
16,160
-68,250
| -81% | -$49.7K | ﹤0.01% | 5935 |
|
|
2024
Q3 | $80.2K | Buy |
84,410
+68,291
| +424% | +$77.5K | ﹤0.01% | 5595 |
|
|
2024
Q2 | $15.7K | Sell |
16,119
-91,443
| -85% | -$100K | ﹤0.01% | 5525 |
|
|
2024
Q1 | $170K | Buy |
107,562
+91,583
| +573% | +$111K | ﹤0.01% | 5150 |
|
|
2023
Q4 | $12.7K | Sell |
15,979
-41,632
| -72% | -$23.5K | ﹤0.01% | 5472 |
|
|
2023
Q3 | $44.9K | Buy |
57,611
+9,534
| +20% | +$8K | ﹤0.01% | 5286 |
|
|
2023
Q2 | $44.5K | Buy |
48,077
+17,332
| +56% | +$20.7K | ﹤0.01% | 5476 |
|
|
2023
Q1 | $33.5K | Sell |
30,745
-110,154
| -78% | -$171K | ﹤0.01% | 5606 |
|
|
2022
Q4 | $206K | Sell |
140,899
-304,294
| -68% | -$493K | ﹤0.01% | 5290 |
|
|
2022
Q3 | $479K | Buy |
445,193
+83,092
| +23% | +$153K | ﹤0.01% | 5015 |
|
|
2022
Q2 | $616K | Buy |
362,101
+2,182
| +0.6% | +$3.75K | ﹤0.01% | 4934 |
|
|
2022
Q1 | $741K | Buy |
359,919
+51,408
| +17% | +$139K | ﹤0.01% | 5062 |
|
|
2021
Q4 | $1.16M | Sell |
308,511
-21,867
| -7% | -$99.5K | ﹤0.01% | 4718 |
|
|
2021
Q3 | $1.71M | Sell |
330,378
-50,783
| -13% | -$228K | ﹤0.01% | 4331 |
|
|
2021
Q2 | $1.62M | Buy |
381,161
+334,023
| +709% | +$1.62M | ﹤0.01% | 4382 |
|
|
2021
Q1 | $250K | Sell |
47,138
-3,910
| -8% | -$22.4K | ﹤0.01% | 5527 |
|
|
2020
Q4 | $275K | Sell |
51,048
-535,395
| -91% | -$2.91M | ﹤0.01% | 4930 |
|
|
2020
Q3 | $4.68M | Buy |
586,443
+147,773
| +34% | +$1.29M | ﹤0.01% | 2959 |
|
|
2020
Q2 | $4.39M | Buy |
+438,670
| New | +$2.75M | ﹤0.01% | 2889 |
|
|
2019
Q4 | – | Sell |
-35,348
| Closed | -$53K | – | 5189 |
|
|
2019
Q3 | $53K | Buy |
35,348
+6,603
| +23% | +$15.4K | ﹤0.01% | 5032 |
|
|
2019
Q2 | $116K | Sell |
28,745
-27,837
| -49% | -$113K | ﹤0.01% | 4899 |
|
|
2019
Q1 | $243K | Buy |
56,582
+21,201
| +60% | +$98.7K | ﹤0.01% | 4719 |
|
|
2018
Q4 | $203K | Buy |
35,381
+9,088
| +35% | +$67.1K | ﹤0.01% | 4822 |
|
|
2018
Q3 | $357K | Sell |
26,293
-15,051
| -36% | -$158K | ﹤0.01% | 4607 |
|
|
2018
Q2 | $491K | Sell |
41,344
-14,313
| -26% | -$178K | ﹤0.01% | 4513 |
|
|
2018
Q1 | $625K | Sell |
55,657
-31,735
| -36% | -$278K | ﹤0.01% | 4348 |
|
|
2017
Q4 | $584K | Buy |
87,392
+37,792
| +76% | +$292K | ﹤0.01% | 4707 |
|
|
2017
Q3 | $406K | Buy |
49,600
+39,349
| +384% | +$246K | ﹤0.01% | 5250 |
|
|
2017
Q2 | $46K | Buy |
+10,251
| New | +$53.6K | ﹤0.01% | 6375 |
|
|
2016
Q3 | – | Sell |
-19,574
| Closed | -$160K | – | 6994 |
|
|
2016
Q2 | $160K | Buy |
+19,574
| New | +$184K | ﹤0.01% | 5851 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Goldman Sachs's ADAP Position: Q4 2025 in Review
Goldman Sachs sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 12,320 shares — an estimated $1.6K sold.
Goldman Sachs first reported a position in ADAP in Q2 2016 and held it in 32 quarters. The position peaked at $4.68M in Q3 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Goldman Sachs reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Goldman Sachs sold 12,320 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.6K.
- Goldman Sachs first reported a position in Adaptimmune Therapeutics in Q2 2016 and held it in 32 quarters.
- Goldman Sachs's Adaptimmune Therapeutics position peaked at $4.68M in Q3 2020.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.